Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! With STAT reporting from ASH this year, we have some stories in the blood space. Also, a potential Dupixent competitor is in the works, and we examine the fallout from Friday’s ACIP meeting. Plus, a SPAC!

The need-to-know this morning

Agios Pharma said the FDA has delayed a decision on the expanded approval of its drug Pyrukynd to treat thalassemia, an inherited blood disorder. The agency missed its Dec. 7 review deadline.

Dyne Therapeutics said its experimental drug for Duchenne muscular dystrophy — a potential next-generation version of Sarepta Therapeutics’ much-debated Exondys 51 — hit the mark in a late-stage study , setting up a potentia

See Full Page